OTCMKTS:DSNKY Daiichi Sankyo 10/30/2026 Earnings Report $17.35 -0.03 (-0.17%) As of 10/5/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Daiichi Sankyo EPS ResultsActual EPSN/AConsensus EPS $0.21Beat/MissN/AOne Year Ago EPSN/ADaiichi Sankyo Revenue ResultsActual RevenueN/AExpected Revenue$3.58 billionBeat/MissN/AYoY Revenue GrowthN/ADaiichi Sankyo Announcement DetailsQuarterDate10/30/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Daiichi Sankyo Earnings HeadlinesDaiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript5 minutes ago | seekingalpha.comMerck, Daiichi Sankyo withdraw US application for lung cancer drugSeptember 25, 2026 | reuters.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Astra-Daiichi breast cancer drug Enhertu recommended for NHS use in EnglandSeptember 17, 2026 | msn.comNew Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular riskAugust 28, 2026 | businesswire.comDaiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization OrganizationAugust 24, 2026 | businesswire.comSee More Daiichi Sankyo Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Daiichi Sankyo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daiichi Sankyo and other key companies, straight to your email. Email Address About Daiichi SankyoDaiichi Sankyo (OTCMKTS:DSNKY) Co., Ltd. is a Japan-based pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Its business is centered on oncology, with additional operations in areas such as cardiovascular disease, immunology, and other serious medical conditions. The company’s oncology portfolio includes antibody-drug conjugates, a technology designed to deliver potent cancer treatments more selectively to tumor cells. Daiichi Sankyo develops and commercializes medicines independently and through collaborations, including its partnership with AstraZeneca on trastuzumab deruxtecan, marketed as Enhertu, for certain cancer indications. Daiichi Sankyo was formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo. The company traces its corporate roots to Japanese pharmaceutical businesses established in the late 19th and early 20th centuries. Headquartered in Tokyo, Daiichi Sankyo serves patients and healthcare providers in Japan and international markets through research, manufacturing, regulatory, and commercial operations.View Daiichi Sankyo ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
